May 21-23, 2024 | New Orleans
Drug Channels readers save 10% with code 24DRCH10*
Whether your daily focus is on Medicaid, Government Pricing, 340B, Drug Price Transparency, Commercial Contracting or Chargebacks, we have you covered! Informa Connect is thrilled to announce Pricing & Contracting USA, an innovative summit that brings together three of the life science industry’s most well-known events (Medicaid & Government Pricing Congress, Drug Pricing Transparency Congress and the Contracts & Chargebacks Summit) together for enhanced learning and networking.
Join us in New Orleans on May 21-23 where you’ll gain critical insight into regulatory requirements, policy initiatives and best practices to enhance pricing and contracting models. Nearly 100 world class speakers are slated to present deep dive sessions, workshops and panels covering these topics and more:
- Wendell Potter, President, Center for Health and Democracy and Publisher, HEALTH un-covered shares an out of the box forecast of upcoming regulations, litigation and policies affecting the industry in what is set to be an action-packed election year.
- Understand the implementation and future of PDABs with Mallinckrodt and the director of the Colorado prescription drug affordability board and the manager of insurance data science.
- Get an OIG Update on AMP cap removal and potential consequences.
- Discuss the nuances of reporting and laws for key Medicaid and GP programs with Genmab and Miree Lee Consulting.
- Listen in as IL HFS Medicaid Drug Rebate Unit reviews rebates, reasonable assumptions, BFSF and best price.
- Hear from Lundbeck, Accord BioPharma, BeiGene and Mirati Therapeutics as they discuss best practices in operating a pricing review board.
- Join Bioventus, Amneal Pharma and CSL Vifor for an overview of the contracting process, types purposes and key considerations.
- Explore the commercial impact of GP decisions and vice versa with Pfizer.
- Hear from PhRMA and BIO on landscape of drug pricing transparency pressures.
- Hyman, Phelps & McNamara review the enforcement and penalties landscape within state drug pricing reporting.
- Novo Nordisk takes a deep dive into confidentiality concerns within SPTR.
- Hear from United Therapeutics and Lundbeck as they discuss synergizing MDRP and SPTR.
- Listen in as Takeda and Sanofi discuss IRA and AMP Cap Removal and how policy changes and evolving regulations will transform the contracting atmosphere.
- And more!
*Cannot be combined with other offers or used towards a current registration. Cannot be combined with special category rates or other offers. Other restrictions may apply.
The content of Sponsored Posts does not necessarily reflect the views of HMP Omnimedia, LLC, Drug Channels Institute, its parent company, or any of its employees. To find out how you can publish a guest post on Drug Channels, please contact Paula Fein (paula@DrugChannels.net).
No comments:
Post a Comment